Alpha Teknova Inc
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Unaudited Condensed Financial Statements
Note 1. Nature of the Business
Teknova produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our product offerings include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products.
Teknova manufactures its products at its Hollister, California, headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister to its customers and distributors.
Note 2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Accounting, Presentation and Use of Estimates
The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with such rules and regulations.
The unaudited condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results may differ from those estimates.
These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the related notes thereto as of and for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2024 (the 2023 Annual Report on Form 10-K). Refer to“Notes to Financial Statements—Note 2. Summary of Significant Accounting Policies,” within the 2023 Annual Report on Form 10-K for a full list of the Company’s significant accounting policies. The information in those notes has not changed except as a result of normal adjustments in the interim periods.
Teknova has determined that it operates in one reporting unit, one operating segment, and one reportable segment, as the Chief Operating Decision Maker (CODM) of the Company reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.
Going Concern
Accounting Standards Codification (ASC) 205-40, Presentation of Financial Statements—Going Concern, requires management to evaluate an entity’s ability to continue as a going concern for the twelve-month period following the date on which the financial statements are available for issuance. Management performed an assessment to determine whether there were conditions or events that, considered individually or in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited financial statements are being issued.
Previous going concern assessments indicated negative conditions and events related to the Company’s limited capital resources to fund ongoing operations and the Company’s ability to comply with future financial covenants under the terms of the Amended Credit Agreement (defined in Note 10), both of which raised substantial doubt about the Company’s ability to continue as a going concern as described in our 2023 Annual Report on Form 10-K. However, the Company was in compliance with its financial covenants under the terms of the Amended Credit Agreement as of September 30, 2024 and as a result of recent business improvements and actions taken by management in the current fiscal year to amend its credit agreement, reduce operating costs, and raise additional capital (as described further in Note 2 below), management believes that there is no longer substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited financial statements are being issued. Debt service requirements in the future require that the Company continues to execute its plans both in terms of operations and financial results. Additionally, unforeseen events or changes in assumptions may occur and result in material differences between the Company’s future financial results or forecasts and the current financial forecast, and those differences could result in management concluding in the future that there is substantial doubt about the Company’s ability to continue as a going concern based upon the new information.
Private Placement Offering
On July 11, 2024, the Company entered into a securities purchase agreement (the Purchase Agreement) and a registration rights agreement in connection with a private placement (the Offering) with certain accredited investors. Pursuant to the Purchase Agreement, the Company agreed to offer and sell in the Offering 12,385,883 shares of the Company’s common stock, $0.00001 par value per share, at an offering price of $1.24 per share. The Company’s controlling stockholder, Telegraph Hill Partners Management Company LLC, through its affiliates Telegraph Hill Partners V, L.P. and THP V Affiliates Fund LLC, the Company’s President and Chief Executive Officer and member of its board of directors, Stephen Gunstream, and the Company’s Chief Financial Officer, Matthew Lowell, participated in the Offering and, collectively, purchased an aggregate of 12,217,740 shares. The Company received aggregate gross proceeds of approximately $15.4 million from the Offering, before deducting offering expenses of $0.2 million. Offering expenses were included as a reduction to additional paid-in capital on the balance sheet. The Offering closed on July 12, 2024.
Reduction in Workforce
On January 11, 2024, the Company carried out a reduction in workforce of approximately 35 positions, aimed at reducing operating expenses. The Company incurred $1.3 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2024, in general and administrative expenses.
On February 1, 2023, the Company carried out a reduction in workforce of approximately 40 positions, aimed at reducing operating expenses. The Company incurred $0.7 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2023, in general and administrative expenses.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging(ASC 815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
Short-term Held-to-Maturity Investments
The Company invests excess cash balances in short-term U.S. Treasuries. Investments are classified based on the facts and circumstances present at the time of purchase. The appropriateness of that classification is subsequently reassessed at each reporting date. As of September 30, 2024, the Company has both the ability and intention to hold these investments until maturity and therefore has classified these investments as held-to-maturity and recorded them at amortized cost which approximates fair value and presented them in “Short-term investments, held -to-maturity” on the balance sheet. The fair value of the Company's short-term investments was based on quoted prices in active markets for these investments(Level 1). The income recognized for these investments is recorded within interest income on the statement of operations.
Accounting Pronouncements Not Yet Adopted
In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Additionally, all disclosure requirements under the guidance are also required for public entities with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company will first apply this standard in the fourth quarter of fiscal 2024 and continues to evaluate the impact this standard will have on the Company’s disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disclosure in the rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciliation items in some categories if the items meet a quantitative threshold. The guidance also requires disclosure of income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. The guidance is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of this standard to determine its impact on the Company’s disclosures.
Recent Securities and Exchange Commission (SEC) Final Rules Not Yet Adopted
In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant’s climate-related risks that have materially impacted, or are reasonably likely to have a material impact on its business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in the registrant’s audited financial statements. Disclosure requirements will begin phasing in for fiscal years beginning on or after January 1, 2025. On April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. The Company is currently evaluating the impact of these new final rules on its financial statements and disclosures.
Note 3. Revenue Recognition
Teknova recognizes revenue from the sale of manufactured products and services when the Company transfers control of promised goods or services to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Control is transferred when the customer has the ability to direct the use of and obtain benefits from the goods or services. The majority of the Company’s sales agreements contain performance obligations satisfied at a point in time when control is transferred to the customer.
Teknova’s revenue, disaggregated by product category, was as follows (in thousands):
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Lab Essentials | $7,161 | $7,274 | $22,065 | $22,112 |
| Clinical Solutions | 1,964 | 597 | 5,247 | 5,859 |
| Other | 451 | 298 | 1,168 | 846 |
| Total revenue | $9,576 | $8,169 | $28,480 | $28,817 |
Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands):
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| United States | $9,057 | $7,827 | $27,155 | $27,628 |
| International | 519 | 342 | 1,325 | 1,189 |
| Total revenue | $9,576 | $8,169 | $28,480 | $28,817 |
Note 4. Concentrations of Risk
Customers
Customers who accounted for 10% or more of the Company’s revenues and outstanding balance of accounts receivable and contract assets are presented as follows:
| For the Three Months Ended September 30, · For the Nine Months Ended September 30, · As of · As of | ||||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | September 30, 2024 | December 31, 2023 | |
| Distributor customer A | 19% | 20% | 18% | 18% | 21% | 16% |
| Distributor customer B | * | * | * | * | 10% | * |
- Represents less than 10%.
The Company’s customers that are distributors, as opposed to direct customers, represent highly diversified customer bases.
Suppliers
Suppliers who accounted for 10% or more of the Company’s inventory purchases and outstanding balance of accounts payable are presented as follows:
| For the Three Months Ended September 30, · For the Nine Months Ended September 30, · As of · As of | ||||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | September 30, 2024 | December 31, 2023 | |
| Distributor supplier A | 37% | 46% | 37% | 39% | 21% | 18% |
| Direct supplier A | 10% | * | 12% | 10% | * | * |
| Direct supplier B | * | 13% | * | 10% | * | * |
- Represents less than 10%.
The Company’s suppliers that are distributors, as opposed to direct suppliers, represent highly diversified supplier bases.
Note 5. Inventories, Net
Inventories consisted of the following (in thousands):
| As of September 30, 2024 | As ofDecember 31, 2023 | |
|---|---|---|
| Finished goods, net | $5,235 | $8,573 |
| Work in process | 134 | 47 |
| Raw materials, net | 2,305 | 2,974 |
| Total inventories, net | $7,674 | $11,594 |
Note 6. Property, Plant, and Equipment, Net
Property, plant, and equipment consisted of the following (in thousands):
| As of September 30, 2024 | As ofDecember 31, 2023 | |
|---|---|---|
| Machinery and equipment | $29,765 | $30,082 |
| Office furniture and equipment | 842 | 842 |
| Vehicles | 340 | 291 |
| Leasehold improvements | 24,915 | 24,673 |
| 55,862 | 55,888 | |
| Less—Accumulated depreciation | (11,439) | (7,528) |
| 44,423 | 48,360 | |
| Construction in progress | 2,292 | 2,004 |
| Total property, plant, and equipment, net | $46,715 | $50,364 |
For the three and nine months ended September 30, 2024, depreciation expense was $1.4 million and $4.1 million, respectively, and for the three and nine months ended September 30, 2023, depreciation expense was $1.3 million and $3.2 million, respectively.
Teknova capitalizes interest on funds borrowed to finance certain of its capital expenditures. Capitalized interest is recorded as part of an asset’s cost and depreciated over the asset’s useful life. For each of the three and nine months ended September 30, 2024, capitalized interest costs were zero and for the three and nine months ended September 30, 2023, capitalized interest costs were not significant and $0.9 million, respectively.
Note 7. Leases
The Company leases office space, warehouse and manufacturing space, and equipment. The Company’s lease agreements have remaining lease terms ofone year to 13 years, and some of these leases have renewal and termination options exercisable at the Company’s election. Terms and conditions to extend or terminate such leases are recognized as part of the right-of-use assets and lease liabilities where reasonably certain to be exercised. All of the Company’s leases are operating leases.
The components of lease expense and other information related to leases were as follows (in thousands):
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating lease expense | $745 | $640 | $2,236 | $2,041 |
| Variable lease expense | 109 | 54 | 326 | 164 |
| Total lease expense | $854 | $694 | $2,562 | $2,205 |
Cash paid for amounts included in the measurement of the lease liabilities was $0.7 million and $2.1 million for the three and nine months ended September 30, 2024, respectively, and cash paid for amounts included in the measurement of the lease liabilities was $0.6 million and $2.1 million for the three and nine months ended September 30, 2023, respectively. The weighted-average discount rate was 5.0% and the weighted-average remaining lease term was 8.2 years as of September 30, 2024.
Maturities of operating lease liabilities at September 30, 2024 were as follows (in thousands):
| Amount | |
|---|---|
| Remainder of 2024 | $703 |
| 2025 | 2,569 |
| 2026 | 2,627 |
| 2027 | 2,631 |
| 2028 | 2,480 |
| Thereafter | 10,296 |
| Total lease payments | 21,306 |
| Less: imputed interest | (4,105) |
| Present value of lease liabilities | $17,201 |
Note 8. Intangible Assets, Net
The following is a summary of intangible assets with definite and indefinite lives (in thousands):
| Balance at September 30, 2024 | Balance at December 31, 2023 | |||||
|---|---|---|---|---|---|---|
| Gross | AccumulatedAmortization | Net | Gross | AccumulatedAmortization | Net | |
| Definite Lived: | ||||||
| Customer relationships | $9,180 | $6,552 | $2,628 | $9,180 | $5,691 | $3,489 |
| Indefinite Lived: | ||||||
| Tradename | 10,750 | — | 10,750 | 10,750 | — | 10,750 |
| Total intangible assets | $19,930 | $6,552 | $13,378 | $19,930 | $5,691 | $14,239 |
For each of the three months ended September 30, 2024 and 2023, amortization expense was $0.3 million and for each of the nine months ended September 30, 2024 and 2023, amortization expense was $0.9 million.
As of September 30, 2024, the remaining weighted-average useful life of definite lived intangible assets was 2.3 years. The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):
| Amount | |
|---|---|
| Remainder of 2024 | $287 |
| 2025 | 1,148 |
| 2026 | 1,148 |
| 2027 | 45 |
| Estimated future amortization expense of definite-lived intangible assets | $2,628 |
Note 9. Accrued Liabilities
Accrued liabilities were comprised of the following (in thousands):
| As of September 30, 2024 | As ofDecember 31, 2023 | |
|---|---|---|
| Payroll-related | $2,712 | $3,826 |
| Property, plant, and equipment | 90 | — |
| Deferred revenue | 34 | 16 |
| Insurance premiums and accrued interest | 222 | 409 |
| Loss contingency accrual | 373 | 300 |
| Other | 942 | 1,028 |
| Total current accrued liabilities | $4,373 | $5,579 |
On July 8, 2024, the Company entered into a financing agreement with First Insurance Funding for the financing of the Company’s D&O liability insurance and related policies. Under the terms of the financing agreement, the Company will pay a total of $0.6 million in premiums, taxes and fees, plus interest at an annual percentage rate of 8.49% in seven monthly separate installment payments commencing on July 25, 2024. During the three months ended September 30, 2024, the Company made a down payment on the policy of $0.2 million to the insurer and three monthly installments for an aggregate of $0.2 million to First Insurance Funding. As of September 30, 2024, the Company owed $0.2 million for insurance premiums and accrued interest.
Note 10. Long-term Debt, Net
On March 8, 2024, the Company entered into limited waivers and amendments (collectively Amendment No. 5) to (i) the May 10, 2022, Amended and Restated Credit and Security Agreement (Term Loan), as amended on November 8, 2022, March 28, 2023, July 13, 2023, and September 19, 2023 and (ii) the May 10, 2022, Amended and Restated Credit and Security Agreement (Revolving Loan) as amended on November 8, 2022, March 28, 2023, July 13, 2023 and September 19, 2023 (together, the Amended Credit Agreement), in each case with the Company as borrower and with MidCap Financial Trust (MidCap) as agent and lender, and the additional lenders from time to time party thereto.
Amendment No. 5 modifies the credit facility established under the Amended Credit Agreement, which provided for a $57.1 million credit facility (the Credit Facility) consisting of a $52.1 million senior secured term loan (the Term Loan) and a $5.0 million working capital facility (the Revolver).
The interest on the Term Loan is based on the forward-looking one-month term Secured Overnight Financing Rate adjusted upward by 0.10% (Term SOFR) plus an applicable margin of 7.00%, subject to a Term SOFR floor of 4.50%. If any advance under the Term Loan is prepaid at any time, a prepayment fee is charged based on the amount being prepaid and an applicable percentage amount, such as 4%, 3%, or 1%, based on the date the prepayment is made. Interest on an outstanding balance under the Revolver is payable monthly in arrears at an annual rate of Term SOFR plus an applicable margin of 4.00%, subject to a Term SOFR floor of 4.50%.
The Amended Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement. Amendment No. 5 reduced the minimum net revenue requirements for future periods up to and including for the twelve months ending December 31, 2024—for example, the Company’s minimum net revenue requirement was reduced for the twelve months ending December 31, 2024, from $42.0 million to $34.0 million. Amendment No. 5 also removed those requirements for the periods ending January 31, 2025 through December 31, 2025, instead requiring that for each applicable twelve-month period ending after December 31, 2024, the Company’s minimum net revenue requirement will be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in the Amended Credit Agreement, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $34.0 million. In addition, Amendment No. 5 also removed the advance rate for finished goods inventory in the determination of the borrowing base for the Revolver and increased the minimum cash requirement from $9.0 million to $10.0 million. Under the terms of the Amended Credit Agreement, cash and cash equivalents as well as short-term investments in U.S. Treasuries are included in the determination of the minimum cash covenant. Finally, Amendment No. 5 conditions the next borrowing under the Revolver on the Company achieving net revenue for the preceding twelve-month period of at least $38.0 million down from $45.0 million. As a condition to the effectiveness of Amendment No. 5, the Company also issued anequity-classified warrant with a fair value of $0.1 millionas described further in “Note 11. Stockholder’s Equity.” This warrant was recorded as additional debt issuance costs, which is being amortized to interest expense over the term of the Amended Credit Agreement using the effective interest method.
The maturity date of the Credit Facility is May 1, 2027. On the date of termination of the Term Loan or the date on which the obligations under the Term Loan become due and payable in full, the Company will pay an exit fee in an amount equal to 9.00% of the total aggregate principal amount of term loans made pursuant to the Term Loan (including amendments thereto) as of such date. All loans issued under the Credit Facility are collateralized by the Company’s assets.
Long-term debt, net consisted of the following (in thousands):
| As of September 30, 2024 | As ofDecember 31, 2023 | |
|---|---|---|
| Term Loan | $12,135 | $12,135 |
| Cumulative accretion of exit fee | 1,472 | 1,261 |
| Unamortized debt discount and debt issuance costs | (222) | (145) |
| Total debt | 13,385 | 13,251 |
| Less: Current portion of long-term debt | (2,528) | — |
| Long-term debt, net of current portion | $10,857 | $13,251 |
At September 30, 2024, the scheduled maturities of the Company’s debt obligations were as follows (in thousands):
| Amount | |
|---|---|
| Remainder of 2024 | $— |
| 2025 | 3,539 |
| 2026 | 6,068 |
| 2027 | 2,528 |
| Total | $12,135 |
As of September 30, 2024, the fair value of the Company’s debt approximated its carrying value. The fair value of the Company’s debt was based on observable market inputs (Level 2).
Note 11. Stockholders’ Equity
At-the-Market Facility
On March 30, 2023, the Company entered into a sales agreement (the ATM Facility) with Cowen and Company, LLC (Cowen), under which the Company may offer and sell, from time to time, shares of its common stock having aggregate gross proceeds of up to $50.0 million. The issuance and sale of these shares pursuant to the ATM Facility are deemed “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the Securities Act), and are registered under the Securities Act. The Company will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the ATM Facility. The aggregate market value of shares eligible for sale under the ATM Facility will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction.
Warrant to Purchase Common Stock
On March 8, 2024, as a condition to the effectiveness of Amendment No. 5, the Company issued to MidCap Funding XXVII a warrant to purchase up to an aggregate of 125,000 shares (the Common Warrant) of common stock with an exercise price of $2.9934 per share, subject to adjustment as provided therein.
The Company determined that the Common Warrant is not a liability within the scope of ASC 480, but met the requirements to be classified within stockholders’ equity, because the warrant is indexed to the Company’s common stock and met all of the conditions for equity classification in accordance with ASC 815. Accordingly, the Common Warrant was recorded as a component of additional paid-in capital in the statements of stockholders’ equity at the time of issuance. The Common Warrant was valued using the Black-Scholes option pricing model with the following assumptions: (i) fair value of common stock of $2.8500, (ii) exercise price of $2.9934, (iii) term of 5 years, (iv) dividend rate of 0%, (v) volatility of 36.70%, and (vi) risk free interest rate of 4.06%.
On October 15, 2024, MidCap exercised the Common Warrant in full and the Company issued 65,036 shares of common stock through a cashless exercise in accordance with the conversion terms.
Note 12. Stock-Based Compensation
Equity Incentive Plans
The Company maintains a stock incentive plan that permits the granting of incentive stock options or nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other stock-based awards. The equity-based awards for employees generally vest over a four-year period, pursuant to two different vesting schedules. For initial equity-based awards granted to employees, the first vest is generally a one-year cliff vest, followed by monthly vesting for the final three years. Thereafter, annual equity-based awards granted to employees typically vest monthly over the four-year vest term. The initial equity-based awards granted to the Company’s non-employee, independent directors upon appointment to the board of directors will vest over a three-year period, with the first vest being a one-year cliff, followed by monthly vesting over the remaining two years. Thereafter, annual equity-based awards granted to the Company’s non-employee, independent directors will cliff vest after one year from the date of grant.
Stock Options
The following table summarizes the stock option activity for the nine months ended September 30, 2024 (in thousands, except share and per share data):
| Number ofShares | WeightedAverageExercisePriceper Share | Weighted AverageRemainingContractualTerm (in years) | AggregateIntrinsicValue (in thousands) | |
|---|---|---|---|---|
| Outstanding at January 1, 2024 | 4,041,807 | $6.41 | 7.53 | $5,159 |
| Granted | 730,100 | $2.86 | ||
| Exercised | (1,779) | $1.97 | ||
| Forfeited | (470,342) | $9.12 | ||
| Expired | (320,156) | $11.94 | ||
| Outstanding at September 30, 2024 | 3,979,630 | $5.00 | 7.08 | $8,262 |
| Exercisable at September 30, 2024 | 2,310,762 | $5.22 | 6.49 | $5,362 |
| Vested and expected to vest at September 30, 2024 | 3,694,948 | $5.35 | 7.29 | $7,013 |
The weighted average assumptions used in the Black-Scholes pricing model for stock options granted during the three and nine months ended September 30, 2024, were as follows:
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Estimated dividend yield · - · % · - · % · - · % · - · % | ||||
| Weighted-average expected stock price volatility | 36.05% | 35.43% | 35.91% | 35.08% |
| Weighted-average risk-free interest rate | 3.49% | 4.54% | 4.33% | 4.15% |
| Expected average term of options (in years) | 6.25 | 3.00 | 6.25 | 5.95 |
| Weighted-average fair value of common stock | $4.40 | $1.95 | $2.86 | $5.05 |
| Weighted-average fair value per option | $1.84 | $0.57 | $1.24 | $2.12 |
Restricted Stock
The following table summarizes the restricted stock unit activity for the nine months ended September 30, 2024 (in thousands, except share and per share data):
| Number ofShares | WeightedAverageGrant Date Fair Valueper Share | Weighted AverageRemainingContractualTerm (inyears) | AggregateIntrinsicValue (in thousands) | |
|---|---|---|---|---|
| Outstanding at January 1, 2024 | 155,780 | $5.05 | 1.36 | $581 |
| Granted | 60,000 | $1.29 | ||
| Vested | (67,169) | $4.58 | ||
| Forfeited | (21,000) | $5.41 | ||
| Outstanding at September 30, 2024 | 127,611 | $3.47 | 1.09 | $618 |
| Vested and expected to vest at September 30, 2024 | 127,611 | $3.47 | 1.09 | $618 |
Employee Stock Purchase Plan
The Company maintains an employee stock purchase plan (ESPP) that authorizes the issuance of shares of common stock pursuant to purchase rights granted to eligible employees. Unless otherwise determined by the Company’s board of directors, shares of the Company’s common stock will be purchased for the accounts of employees participating in the Company’s ESPP at a price per share equal to the lesser of (i)85% of the fair market value of a share of the Company’s common stock on the first day of an offering; or (ii)85% of the fair market value of a share of the Company’s common stock on the date of purchase. Offering periods are generally six months long; offering periods begin on June 1 and December 1 of each year. The Company issued zero and 54,314 shares of common stock under the ESPP during the three and nine months ended September 30, 2024, respectively. The Company issued zero and 82,034 shares of common stock under the ESPP during the three and nine months ended September 30, 2023, respectively.
Repricing of Outstanding and Unexercised Options
In January 2024, the Company’s board of directors approved a one-time repricing of certain previously granted and still outstanding vested and unvested stock option awards held by eligible employees, executive officers, and non-employee directors. As a result, the exercise price for these awards will be lowered to $2.97 per share effective September 14, 2025, which was the closing price of the Company’s common stock as reported on the Nasdaq Global Stock Market on March 14, 2024, so long as the holder remains employed by the Company or continues to serve as a member of the board of directors through September 14, 2025 absent earlier trigger events defined in the option repricing plan. No other terms of the stock options were modified, and the stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing,1,631,016 vested and unvested stock options outstanding as of March 14, 2024, with original exercise prices ranging from $3.02 to $27.49, were repriced.
The repricing on March 14, 2024, resulted in incremental stock-based compensation expense of $0.9 million, of which $0.5 million related to vested stock option awards and was expensed on the repricing date. The remaining $0.4 million related to unvested stock option awards and is being amortized on a straight-line basis over the weighted-average vesting period of those awards of approximately 2.38 years as of March 14, 2024.
Stock-Based Compensation Expense
Stock-based compensation expense included in the accompanying condensed financial statements was as follows (in thousands):
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Cost of sales | $10 | $36 | $89 | $112 |
| Research and development | 18 | 43 | 65 | 120 |
| Sales and marketing | 33 | 168 | 162 | 492 |
| General and administrative | 699 | 788 | 2,584 | 2,391 |
| Total stock-based compensation expense | $760 | $1,035 | $2,900 | $3,115 |
Stock-based compensation expense related to stock options was $0.7 million and $2.7 million for the three and nine months ended September 30, 2024, respectively, and $0.9 million and $2.8 millionfor the three and nine months ended September 30, 2023, respectively. Unrecognized compensation expense related to stock options was $4.6 million at September 30, 2024, which is expected to be recognized as expense over the weighted-average period of 2.90 years.
Stock-based compensation expense related to restricted stock units was $0.1 million and $0.2 million for the three and nine months ended September 30, 2024, respectively, and $0.1 million and $0.2 million for the three and nine months ended September 30, 2023, respectively. Unrecognized compensation expense related to restricted stock units was $0.4 million at September 30, 2024, which is expected to be recognized as expense over the weighted-average period of 1.62 years.
Stock-based compensation expense related to the ESPP was not significant for the three or nine months ended September 30, 2024, respectively, and not significant and $0.1 million for the three and nine months ended September 30, 2023, respectively. Total compensation cost related to the ESPP not yet recognized was not significant at September 30, 2024. As of September 30, 2024, an insignificant amount has been withheld on behalf of employees for future purchases under the ESPP.
Note 13. Income Taxes
For the three months ended September 30, 2024, the Company’s income tax benefit was not significant, compared to the three months ended September 30, 2023, when the Company recorded a minimal income tax provision. The effective tax rates for the three months ended September 30, 2024 and 2023 were 0.1% and (0.1)%, respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit.
For the nine months ended September 30, 2024, the Company’s income tax benefit was not significant, compared to the nine months ended September 30, 2023, when the Company recorded a minimal income tax provision. The effective tax rates for the nine months ended September 30, 2024 and 2023 were 0.2% and (0.0)%, respectively. The effective tax rates differ from the federal statutory rate primarily due to operating losses not expected to produce an income tax benefit.
The Company had insignificant unrecognized tax benefits as of September 30, 2024 and 2023. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not expect the balance of unrecognized tax benefits to change significantly over the next twelve months. The Company has not accrued interest or penalties related to uncertain tax positions as of September 30, 2024 or 2023.
Note 14. Net Loss Per Share
Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents to the extent they are dilutive. For purposes of this calculation, stock options, restricted stock units, employee stock purchase rights, and warrants to purchase common stock, are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.
The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net loss | $(7,565) | $(10,153) | $(21,026) | $(26,124) |
| Weighted average shares used in computing net loss per share—basic and diluted | 51,821,395 | 29,956,930 | 44,520,132 | 28,810,068 |
| Net loss per share—basic and diluted | $(0.15) | $(0.34) | $(0.47) | $(0.91) |
The following is a summary of the common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive:
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Employee share-based awards to purchase common stock | 3,873,226 | 4,019,909 | 3,970,116 | 4,000,857 |
| Warrants to purchase common stock | 125,000 | — | 94,434 | — |
Note 15. Related Parties
The Company has identified Meeches LLC (Meeches) as a related party through common control. Meeches is controlled by Ted Davis and Irene Davis. Irene Davis is a former officer and current director, Ted Davis is a founder and former director, and both are greater than five percent stockholders of the Company. Prior to May 16, 2023, the Company leased certain real property in Mansfield, Massachusetts, from Meeches. For each of the three and nine months ended September 30, 2024, the Company didnot make any lease payments to Meeches. For the three and nine months ended September 30, 2023, the Company paid Meeches lease payments zero and $0.1 million, respectively.
Note 16. Contingencies
From time to time, we may become involved in lawsuits and other claims arising from our ordinary course of business. The Company regularly evaluates its exposure to threatened or pending litigation and other business contingencies. Because of the uncertainties related to the amount of loss from litigation and other business contingencies, the recording of losses relating to such exposures requires significant judgment about the potential range of outcomes. We establish loss provisions for matters in which losses are probable and can be reasonably estimated. If a loss is not both probable and reasonably estimable, or if an exposure to loss exists in excess of the amount accrued, the Company assesses whether there is at least a reasonable possibility that a loss, or additional loss, may have been incurred. If there is a reasonable possibility that a loss, or additional loss, may have been incurred, the Company will disclose the estimate of the possible loss or range of loss if it is material and an estimate can be made, or disclose that such an estimate cannot be made. The determination as to whether a loss can reasonably be considered to be possible or probable is based on our assessment, together with legal counsel, regarding the ultimate outcome of the matter. As additional information about current or future litigation or other contingencies becomes available, the Company will assess whether adjustments should be made to legal accruals.
In August 2023, a former Teknova employee filed a claim with the California Labor and Workforce Development Agency alleging various causes of action under California’s labor, wage, and hour laws. The plaintiff generally alleged that Teknova did not appropriately calculate and pay meal break premiums and otherwise failed to calculate and pay appropriate overtime wages or bonusesto certain of its California non-exempt employees. As of December 31, 2023, the Company had accrued its best estimate of potential loss related to a possible settlement of the claims of the former employee and other employees who may assert similar claims, in the amount of $0.3 million, which is included within “Accrued liabilities” on the Balance Sheet. On June 6, 2024, a mediation took place, in the course of which Teknova agreed to settle theplaintiff’s claims for $0.4 million (the Settlement), resulting in an incremental accrual of $0.1 million during the three months ended June 30, 2024. Because the plaintiff brought his claims on behalf of himself as an individual and as a representative of a purported class of others similarly situated, a court must approve the Settlement before Teknova will pay any amounts pursuant to the Settlement. As of September 30, 2024, the Company has therefore accrued $0.4 million within “Accrued liabilities” on the Balance Sheet.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.